prime medicine(PRME) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates -- Initial data from Phase 1/2 trial of PM359 for p47 CGD expected in 2025 -- phox -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 – Cambridge, Mass., May 08, 2024 – Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one ...